← Russell 3000 cross-section

SYK STRYKER CORP

Trailing twelve months to 2026-06-30 · as filed 2026-07-31, not restated
Healthcare

Scale

Market cap
$125.2bn
Revenue TTM
$25.8bn
Net income TTM
$3.7bn
Free cash flow
$4.7bn
Composite score
54.2
Sector rank
#98

Valuation

P / E
33.6
EV / EBITDA
19.1
EV / sales
5.3
FCF yield
3.76%
Earnings yield vs 10-yr
-1.75pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
14.4%
EBITDA margin
27.7%
ROE
15.6%
ROIC
15.6%
Revenue growth
8.5%

Insider activity, last 90 days

Net open-market
$-118.20m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Revenue related to customer lease agreements sold under these arrangements represented less than 4 % of our total revenue for the three and six months 2026 and 2025 . The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using segment operating income. Our goal is to achieve sales growth at the high- end of the medical technology (MedTech) industry and maintain our long-term capital allocation strategy that prioritizes: (1) Acquisitions, (2) Dividends and (3) Share repurchases. Overview of the Three and Six Months In the three months 2026 we achieved sales growth of 9.4% from 2025 . …STRYKER CORP, 10-Q, period ended 2026-06-30, filed 2026-07-31

Read the full passage →